Literature DB >> 20171403

Non-melanoma skin cancer.

Vishal Madan1, John T Lear, Rolf-Markus Szeimies.   

Abstract

The rising incidence and morbidity of non-melanoma skin cancers has generated great interest in unravelling of their pathogenesis and in the search for new non-invasive treatments. Whereas the role of cumulative sun exposure in pathogenesis of squamous-cell carcinoma seems clear, the relation between sun-exposure patterns and subtypes of basal-cell carcinoma remains undetermined. Several complex genotypic, phenotypic, and environmental factors contribute to pathogenesis of non-melanoma skin cancers. Unlike basal-cell carcinoma, squamous-cell carcinomas can arise from precursor lesions. Diagnosis of non-melanoma skin cancer is made clinically and confirmed by histological testing. Prognosis depends on lesion and host characteristics, which also dictate choice of treatment. Prevention strategies aim at reduction of sun exposure, but are of unproven benefit, especially for basal-cell carcinoma. Surgical excision with predetermined margins is the mainstay of treatment for squamous-cell carcinoma and for most basal-cell carcinomas. Of the new non-invasive treatments, only photodynamic therapy and topical imiquimod have become established treatments for specific subtypes of basal-cell carcinoma, and the search for more effective and tissue-salvaging therapies continues. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20171403     DOI: 10.1016/S0140-6736(09)61196-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  197 in total

1.  Nuclear morphometry identifies a distinct aggressive cellular phenotype in cutaneous squamous cell carcinoma.

Authors:  Evan S Glazer; Peter H Bartels; Anil R Prasad; Michael L Yozwiak; Hubert G Bartels; Janine G Einspahr; David S Alberts; Robert S Krouse
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-02

2.  Lesion dimensions following ablative fractional laser treatment in non-melanoma skin cancer and premalignant lesions.

Authors:  Katrine Togsverd-Bo; Uwe Paasch; Christina S Haak; Merete Haedersdal
Journal:  Lasers Med Sci       Date:  2011-10-01       Impact factor: 3.161

3.  Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; María Jiménez; Latifa Bakiri; Peter Petzelbauer; Erwin F Wagner
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

4.  Label-free DNA imaging in vivo with stimulated Raman scattering microscopy.

Authors:  Fa-Ke Lu; Srinjan Basu; Vivien Igras; Mai P Hoang; Minbiao Ji; Dan Fu; Gary R Holtom; Victor A Neel; Christian W Freudiger; David E Fisher; X Sunney Xie
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

5.  A retrospective analysis of occupational exposure to pesticides as a possible risk factor for non-melanoma skin cancers.

Authors:  Manigreeva Krishnatreya; Amal C Kataki; Jagannath D Sharma; Kaberi Lahkar
Journal:  South Asian J Cancer       Date:  2015 Jan-Mar

6.  Toll-like receptor 7 mediates pruritus.

Authors:  Tong Liu; Zhen-Zhong Xu; Chul-Kyu Park; Temugin Berta; Ru-Rong Ji
Journal:  Nat Neurosci       Date:  2010-10-31       Impact factor: 24.884

7.  Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma.

Authors:  K A Su; L A Habel; N S Achacoso; G D Friedman; M M Asgari
Journal:  Br J Dermatol       Date:  2018-08-14       Impact factor: 9.302

8.  Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies.

Authors:  Huilin Tang; Shuangshuang Fu; Suodi Zhai; Yiqing Song; Jiali Han
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

9.  Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.

Authors:  Beatrice Nardone; Sara Majewski; Ashley S Kim; Tina Kiguradze; Estela M Martinez-Escala; Rivka Friedland; Ahmad Amin; Anne E Laumann; Beatrice J Edwards; Alfred W Rademaker; Mary C Martini; Dennis P West
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

10.  Targeted deletion of RasGRP1 impairs skin tumorigenesis.

Authors:  Amrish Sharma; Lauren L Fonseca; Cynthia Rajani; Jodi K Yanagida; Yuka Endo; J Mark Cline; James C Stone; Junfang Ji; Joe W Ramos; Patricia S Lorenzo
Journal:  Carcinogenesis       Date:  2014-01-24       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.